Observations on the use of Bruton’s tyrosine kinase inhibitors in SAR-CoV-2 and cancer

Journal of Hematology & Oncology

Brooke Benner¹  William E. Carson² 

[1] Comprehensive Cancer Center, The Ohio State University;Department of Surgery, Division of Surgical Oncology, The Ohio State University;

关键词: Bruton’s tyrosine kinase;    Sars-CoV-2;    COVID-19;    Cancer;    Ibrutinib;    Acalabrutinib;   

DOI  :  10.1186/s13045-020-00999-8

来源: DOAJ

【 摘 要 】

Abstract Bruton’s tyrosine kinase (BTK) inhibitors, drugs utilized in cancer, are being repurposed for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) (COVID-19). Recently, BTK inhibitors acalabrutinib and ibrutinib have been found to protect against pulmonary injury in a small group of patients infected with SARS-CoV-2. The high levels of pro-inflammatory cytokines found in the circulation of COVID-19 patients with severe lung disease suggest the involvement of the innate immune system in this process. Understanding the potential mechanism of action of BTK inhibition in SARS-CoV-2 is clearly of importance to determine how acalabrutinib, ibrutinib and possibly other BTK inhibitors may provide protection against lung injury.

【 授权许可】

Unknown